



Drug Prior Authorization Committee Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
December 15, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[* Click HERE for Meeting Documents *](#)

Committee Members Present

Angeline Stanislaus, MD
J.K. Sturgeon, PharmD, BCPS
James Krings, MD, MSc
Laura Kingsley, PharmD
Maya Moody, DO, FAAP
Morgan Sperry, PharmD
Nicole Tran, PharmD

Committee Members Absent

Conrad Balcer, DO, Chair
Matthew Stinson, MD

MO HealthNet Staff Present

Angela Wilson, Pharmacy Operations Manager
Becky Carter, Medicaid Drug Rebate Senior Specialist
Carmen Burton, Pharmacy Support Assistant
Connie Sutter, Fiscal Manager
Desiree Vitale, Special Counsel
Elizabeth Short, Program Development Specialist
Elizabeth Sissom, RN, Clinical Review Nurse
Jaime Jones, Drug Rebate Medicaid Specialist
Joshua Moore, PharmD, Director of Pharmacy
Katherine Heriford, Pharmacy Benefit Specialist
Lisa Smith, Pharmacy RFP Coordinator
Mark Roaseau, R.Ph., Clinical Pharmacist
Nikki Ashley, Pharmacy Program Specialist
Olivia Rush, PharmD, Program Integrity Pharmacist
Pat Borgmeyer, Medicaid Drug Rebate Senior Specialist
Shannon McDonald, Medicaid Drug Rebate Senior Specialist
Tabatha Whisler, Medicaid Drug Rebate Senior Specialist
Timothy Kling, MD, Acting Medical Director
Vicki Benz, Medicaid Drug Rebate Senior Specialist

Contractors Present

Amanda Williams, PharmD, RPh, GWT
Ashley Lytton, RN, BSN, Wipro
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Jennifer Colozza, PharmD, Conduent
John Crowley, PharmD, BCPS, CPPS, Conduent
Karen Powell, PharmD, MS, GWT
LeAnna Kirsch, RN, Wipro
Lokendra Upadhyay, PharmD, Conduent
Lynn Morsches, PharmD, Conduent
Mandy Nilges, RN, Wipro
Mary-Beth Plum, PharmD, Conduent
Megan Fast, PharmD, GWT
Paul Fung, PharmD, MHA Conduent
Sandy Kapur, PharmD, GWT
Serena Barden, PharmD, BCPS, GWT
Vicki Revel, PharmD, GWT

Others Present:

Akesha Coleman	Cindy Pennington	Jomy Joseph	Michele Shirley
Amanda Nowakowski	Dave Miley	Jordon Wild	Nicole Jones
Amber Towe	Dave Poskey	Joshua Stolker	Phillip Lohec
Angela Moissis	David DiBernardo	Julie Waterbury	Richard Page
Ashlee	David Large	Kathryn Harness	Richie Crawford
Audrey Rattan	Devechio Edwards	Kathi Honess	Ricki Roberson
Azfar Malik	Elizabeth Foster	Keith Gulley	Robert Pearce
Beth D'Ambrosio	Erin Hohman	Keith Powell	Rusty Hailey
Beth Kingeter	Erise Williams	Kenneth Berry	Shauna Williams
Bill Neubach	Fabiola Garcia	Kevin Gallagher	Shelly Nickerson
Biran Patel	Folger Tuggle	kfrye	Steve Henroid
Brad Hornaday	Gary Parenteau	Kim Witte	Susie Moroney
Brad Willie	GLO	Kurt Hendrickson	Suzzane Tiller
Brett Lundsten	Heather Pezewski	Lance Salazar	Tami Sova
Brian Strickland	Jamie Tobitt	Lee Ward	Terry
Brooke Wilkins	Jen Tamburo	Lisa Willshaw	TMC Pharmacy
Bryan	Jenny Carrell	Mark Gies	Tom Seignious
Carla Schad	Jessica Petrie	Mary Kaneaster	Tyler Craddock
Casey Prough	Jim Sharp	Matifadza Hlatshwayo-Davis	William Wynn
Chelsea Leroue	John Deason	Melissa Basil	
Christine Galeotti	John Flatt	Meredith Voss	
Cindi Pearson	John Schillo	Michah Lands	

Welcome, Announcements and Introductions	Joshua Moore, MHD Director of Pharmacy, called the meeting to order, introduced himself along with James Krings, the newest Committee member, and facilitated the meeting on behalf of the MO HealthNet Division. Additionally, Morgan Sperry introduce her pharmacy student, Vance Howerton.
Minutes Review	Discussion: Minutes were reviewed from the September meeting. Decision: The Committee voted to accept these approved minutes with no revisions.
Election of New Chair	Conrad Balcer retired after 22 years with the Drug Prior Authorization Committee. Discussion: A motion was made by JK Sturgeon and seconded by Morgan Sperry to elect Laura Kingsley as the new Committee Chair. Laura accepted the motion. Decision: The Committee voted to elect Laura Kingsley as the new Committee Chair.
Pharmacy Program and Budget Update	Elizabeth Short, Joshua Moore and Elizabeth Sissom presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included: - October 2022 Enrollees and Expenditures - July – October 2022 Expenditures by Service - October 2022 Medicaid Expansion Participants, Expenditures, and Claim Count - Pharmacy Program Top 4 Drug Classes per Fiscal Year (FY) - July 2022 – November 2022 Pharmacy Expenditures - July 2022 – November 2022 Pharmacy Specialty and Non-Specialty Expenditures - Mavyret Expenditures per FY - November 2022 Top Ten Reimbursed Drugs for Children 0-17 - FY2020 – FYTD2023 Rare Disease Expenditures Per Day - Prior Authorization Process and Updates
Old Business	

Old Business	Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations. These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm
New Business	
New Drug Review	Discussion: - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. - o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Committee for discussion and action. - No other discussion. - Public comment provided by: - o Bill Neubach with Accord Healthcare on Camcevi Decision: The Committee voted to accept the presented new drug recommendations with no revisions.
Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	Discussion: - Joshua Moore introduced the edits for discussion to the Committee which included: - o Aduhelm Clinical Edit

	○ Antipsychotics, 1st Generation (Typical) Clinical Edit ○ Benzodiazepine, Select Oral Clinical Edit ○ Butalbital Combinations without Codeine Clinical Edit ○ Corlanor Clinical Edit ○ Empaveli Clinical Edit ○ HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit ○ High Risk Therapies Clinical Edit ○ Kerendia Clinical Edit ○ Morphine Milligram Equivalent (MME) Accumulation Clinical Edit ○ Non-Oral Contraceptives Fiscal Edit ○ Oxazolidinone Fiscal Edit ○ Pompe Disease Clinical Edit ○ Selzentry Clinical Edit ○ Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit ○ Verquvo Clinical Edit - No other discussion. - Public comment provided by: ○ Jamie Tobitt with Apellis on Empaveli yielded time back Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Camzyos Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Opioids, Short Acting Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion.

	- No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Skysona Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Xenpozyme Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Ztalmy Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o John Flatt with Marinus Pharmaceuticals Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Zynteglo Clinical Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o Biran Patel with Bluebird Bio Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Resource List Edit Review	

Antipsychotics – 2nd Generation (Atypical) Depot Agents	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o Kenneth Berry with Alkermes on Aristada and Aristada Initio Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Antipsychotics – 2nd Generation (Atypical) Oral and Transdermal Agents	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o Kenneth Berry with Alkermes on Lybalvi - o Erin Hohman with Abbvie on Vraylar - o Casey Prough with White Oak Psychiatric Services on Caplyta - o Amber Towe with White Oak Psychiatric Services on Caplyta - o Micah Lands with Intra-Cellular on Caplyta - o Gena Terlizzi with NAMI Missouri - o William Wynn with Indivior yielded time back Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Preferred Drug List Edit Review	
Preferred Drug Edits With No Annual Changes	Discussion: - Joshua Moore introduced the edits for discussion to the Committee which included: - o Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists & Combinations PDL Edit - o Antiemetics, 5-HT3 and NK1 Injectables PDL Edit - o Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit - o Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit - o Anti-Parkinsonism, MAO-B Inhibitors PDL Edit - o Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit

	○ Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit ○ Glucagon Agents PDL Edit ○ Hereditary Angioedema Agents PDL Edit ○ NSAIDs PDL Edit ○ Opioid Emergency Reversal Agents PDL Edit ○ Opioids, Long Acting PDL Edit ○ Somatostatin Analogs PDL Edit ○ Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit - Public comment provided by: ○ David Miley with Teva on Austedo yielded time back ○ John Deason with Neurocrine Biosciences on Ingrezza ○ Julie Waterbury on Ingrezza ○ Azfar Malik with CenterPoint on Ingrezza and Austedo Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Antiandrogenic Agents PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Anticonvulsants, Dravet Syndrome PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: ○ Carla Schadt with UCB Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Anti-Migraine, Alternative Oral Agents PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: ○ Chelsea Leroue with Biohaven on Nurtec ODT yielded time back ○ Erin Hohman with Abbvie on Ubrelvy

	Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Antiplatelet Agents PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - Public comment provided by: - o Joshua Stolker with Mercy on Brilinta - o Lisa Willshaw with AstraZeneca on Brilinta - Maya Moody proposed to keep Brilinta as a preferred product. Decision: The Committee voted to accept the recommended criteria with the proposed revision.
Antiretroviral Therapy (ART) PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o Erise Williams with Williams and Associates INC on Symtuza Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o David Miley with Teva on Ajovy yielded time back - o Jordon Wild with Amgen on Aimovig - o Erin Hohman with Abbvie on Qulipta Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Fibromyalgia Agents PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No public comment provided. - Laura Kingsley proposed to updated the pregabalin max dose to 675mg. Decision: The Committee voted to accept the recommended criteria with the proposed revision.

GI Motility Agents, Chronic PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Neuropathic Pain PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No public comment provided. - Maya Moody proposed to update max quantities to match max limits. Decision: The Committee voted to accept the recommended criteria with proposed revisions.
Opioid & Select Alcohol Dependence Agents PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o William Wynn with Indivior on Sublocade yielded time back Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Sedative Hypnotics PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: - o Keith Powell with Idorsia Pharmaceuticals on Quviviq Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Skeletal Muscle Relaxants PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion.

	- No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Tramadol-Like Agents PDL Edit	Discussion: - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. Decision: The Committee voted to accept the recommended criteria with no additional revisions.
Other Business	
Program Utilization Information – Conduent Update	Jennifer Colozza with Conduent presented the following items for review: - Top 25 Drugs by Paid Amount 1st Quarter SFY23 (July, August, September) - Top 25 Drugs by Paid Number 1st Quarter SFY23 (July, August September) - Call Center User Statistics November 2022 - CyberAccess Logging Information - New Drug Statistics November 2022
Adjournment	Laura Kingsley motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via hybrid meeting (in person and WebEx) on Tuesday, April 18, 2023.

NEXT MEETING: Tuesday, April 18, 2023

615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

Roll Call for December 15, 2022									
	<u>Committee Member</u>								
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody	Nicole Tran	James Krings
September Meeting Minutes	A	SY	MY	Y	A	Y	Y	Y	Y
Election of New Chair	A	AB	SY	Y	A	MY	Y	Y	Y
New Drug Review	A	Y	Y	SY	A	Y	MY	Y	Y
Block Vote for Clinical and Fiscal Edits, No Annual Changes	A	SY	Y	Y	A	MY	Y	Y	Y
Block Vote for Clinical and Fiscal Edits, Annual Changes	A	Y	MY	Y	A	SY	Y	Y	Y
Block Vote for Resource List Edits, Annual Changes	A	Y	Y	SY	A	MY	Y	Y	Y
Block Vote for Preferred Drug List Edits, No Annual Changes	A	SY	Y	Y	A	Y	MY	Y	Y

Roll Call for December 15, 2022

	<u>Committee Member</u>								
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody	Nicole Tran	James Krings
Block Vote for Preferred Drug List Edits, Annual Changes	A	Y	Y	Y	A	SY	MY	Y	Y
Closing	A	MY	Y	SY	A	Y	Y	Y	Y
Adjournment	A	Y	MY	Y	A	SY	Y	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain